Development of an ultra-high dose rate rotational linac for flash radiotherapy
Ended Project Grant Awarded Last action
- Award ID
- R01CA255432
- Recipient
-
The Regents Of The University Of California. San Francisco UEI KMH5K9V7S518 Part of State Of California Controllers Office
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $12,525,891
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Funding
-
- $11,931,170.53 Federal
- $594,720.00 Non-federal
- Place of performance
- San Francisco, CA 94143, USA
Award details come from USAspending.gov.
Description
- Abstract
- Radiotherapy is used to treat 60% of the cancer patients and 40% of curative cases. However, normal tissue toxicities still prevent radiotherapy from achieving more effective tumor control in many patients despite decades of technological development in intensity-modulated radiation therapy and image-guided radiation therapy. Ultra- high dose rate, A.K.A., flash radiotherapy has recently RE-emerged as a potential method to significantly improve the radiation biological dose conformality on top of the physical dose conformality. Although existing x- RAY linac and proton systems can be modified to deliver the flash dose rate, they are limited in either field size, depth penetration, or dose conformality to be useful for treating most human tumors. Conceptual systems such as very high energy electron and phaser will need to overcome significant and risky technological barriers to be clinically practical. In this academic-industrial partnerships project, we propose to develop a high dose rate x-RAY radiotherapy system that is a scale-up of existing technologies for clinical flash radiotherapy. There are three major technical challenges in achieving the flash dose rate with x-rays. The first is the linear accelerator that is capable to produce such a high dose rate. For this challenge, we hypothesize that a 12 MV x-RAY beam >300 GY/s uncollimated dose rate can be achieved using a combination of already-demonstrated accelerator technologies. The second challenge is the well-separated beam angles for good x-RAY dosimetry. The third challenge is intensity modulation for conformal dose distribution. The tightly correlated second and third challenges are due to the slow mechanical movement of the common c-arm gantry and the MLC leaf speed. To overcome these two challenges, we propose to develop a rotational ring-gantry flash imrt platform with many quasi-static mlcs. The fast-spinning ring-gantry system would deliver the entire treatment in an ARC within a very short time. The intensity modulation is achieved by using a decoupled MLC ring with a large number of MLC banks each pre-shaping the aperture for rotational imrt. The system would then be able to achieve highly conformal dose distribution comparable to state of the art vmat, and at the same time take advantage of the flash radiobiology. We propose the following aims: aim 1. High dose rate linac development; aim 2. Development of rotational direct aperture optimization with a decoupled (road) MLC ring; aim 3. Demonstration of rotational flash using a benchtop system.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $58,853 | |
| Amendment | $58,853 | |
| Amendment | $58,853 | |
| Amendment | $529,672 | |
| Amendment | $529,672 | |
| Amendment | $529,672 | |
| Amendment | $529,672 | |
| Amendment | -$164,474 | |
| Amendment | $0 | |
| Amendment | $164,474 | |
| Amendment | -$164,474 | |
| Amendment | $0 | |
| Amendment | $164,474 | |
| Amendment | $164,474 | |
| Amendment | $34,991 | |
| Amendment | $34,991 | |
| Amendment | $34,991 | |
| Amendment | $34,991 | |
| Amendment | $629,825 | |
| Amendment | $629,825 | |
| Amendment | $629,825 | |
| Amendment | $629,825 | |
| Amendment | $629,825 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $746,767 | |
| Amendment | $746,767 | |
| Amendment | $0 | |
| Amendment | $746,767 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $746,767 | |
| Amendment | $746,767 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $47,513 | |
| Amendment | $47,513 | |
| Amendment | $47,513 | |
| Amendment | $47,513 | |
| Amendment | $534,517 | |
| Amendment | $534,517 |
Show 40 more
Latest 50 listed here. See the rest on GovTribe.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Radiabeam Technologies, LLC | $758,484 | |
| Radiabeam Technologies, LLC | $322,434 |
Quick answers
Who received award R01CA255432?
R01CA255432 was awarded to The Regents Of The University Of California. San Francisco by National Cancer Institute (National Institutes of Health) on March 15, 2021.
How much is award R01CA255432 worth?
$12,525,891 has been obligated on R01CA255432: $11,931,171 in federal funding and $594,720 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award